Press Release
8 September 2021
Immunicumandthe University Medical Center GroningenReceive a Grant from Health~Hollandto Broaden Cancer Relapse Vaccine Development for Ovarian Cancer
Immunicum AB (publ; IMMU.ST) announced today that it has initiated a new research collaboration with theUniversity Medical Center Groningen (UMCG), toexplorenovel treatment options for ovarian cancer based on the combination of Immunicum's cell-based cancer vaccine platform with immune checkpoint inhibitors (CPI).The project is supported by a grant fromHealth~Holland, Top Sector Life Sciences & Health (LSH).
The 3-year preclinical research project will be conducted together with the laboratory of Dr. Marco de Bruyn and Prof. Dr. Hans W. Nijman at UMCG, Department of Obstetrics & Gynecology. Under the terms of the agreement, Immunicum will combine its expertise in allogeneic dendritic cell and T cell biology with UMCG's research experience in ovarian cancer and targeted genomic modulation, in order to elucidate potential synergies between Immunicum's lead cancer relapse vaccine candidate DCP-001, and CPIs in ovarian cancer.
"This collaboration extends our existingrelationship with UMCG and supports the development of cancer relapse vaccination as a novel approach for the treatment of ovarian cancer. It also exemplifies Immunicum's commitment to continue to invest in its academicpartnerships," said Alex Karlsson-Parra, Chief ScientificOfficer at Immunicum.
Immunicum has an ongoing clinical collaboration with UMCG for the ALISON study, a single-center, open-label Phase I study evaluating safety and efficacy of DCP-001 in High-Grade Serous Ovarian Cancer (HGSOC) patients. Immunicum and UMCG had previously completed a preclinical research study demonstrating the stimulation of immune responses against ovarian cancer cells by DCP-001. The data from this study will be presented at the upcoming European Society for Gynaecological Oncology conference, held October 23-25.
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
Telephone: +31 713 322 627
E-mail: ir@immunicum.com
INVESTOR RELATIONS
Kristina Windrup Olander
Spikinc AB
Telephone: +46 72 545 34 74
E-mail: ir@immunicum.com
MEDIA RELATIONS
Sophia Hergenhan & Jacob Verghese
Trophic Communications
Telephone: +49 160 90816161
E-mail: immu@trophic.eu
ABOUT HEALTH~HOLLAND, TOP SECTOR LIFE SCIENCES & HEALTH (LSH)
The Health~Holland, Top Sector LSH grant, known as PPP-Allowance or TKI-toeslag, is awarded to fund multidisciplinary public private partnerships and to stimulate innovative, interdisciplinary research and development by bringing together stakeholders in a shared, consolidated innovation infrastructure. The Top Consortia for Knowledge and Innovation
ABOUT UMCG
The University Medical Center Groningen
ABOUT IMMUNICUM AB (PUBL)
Immunicum is leveraging its unparalleled expertise in allogeneic dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
Attachment
- 20210908_Immunicum_UMCG Collaboration_ENG (https://ml-eu.globenewswire.com/Resource/Download/e1bd3ac3-0682-4b80-b802-07f41e78bf49)
